Enlicitide Decanoate + Placebo
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolemia (HeFH)
Conditions
Heterozygous Familial Hypercholesterolemia (HeFH)
Trial Timeline
Aug 21, 2025 → Jan 23, 2037
NCT ID
NCT07058077About Enlicitide Decanoate + Placebo
Enlicitide Decanoate + Placebo is a phase 2/3 stage product being developed by Merck for Heterozygous Familial Hypercholesterolemia (HeFH). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07058077. Target conditions include Heterozygous Familial Hypercholesterolemia (HeFH).
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07058077 | Phase 2/3 | Recruiting |
| NCT06008756 | Phase 3 | Active |
| NCT05952856 | Phase 3 | Completed |
| NCT05952869 | Phase 3 | Completed |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolemia (HeFH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Fluvastatin | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Evolocumab + Placebo | Amgen | Phase 3 | 76 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 76 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 32 |
| IBI306 + placebo | Innovent Biologics | Phase 3 | 76 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 76 |
| LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo | Sanofi | Phase 3 | 76 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 76 |
| Praluent | Sanofi | Approved | 84 |
| AK102 + Placebo + Statins and/or Ezetimibe | Akeso | Phase 2 | 51 |
| lerodalcibep | Medpace | Phase 3 | 74 |
| mipomersen sodium + placebo | Ionis Pharmaceuticals | Phase 3 | 74 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 49 |